Krusche M, Ruffer N, Grahammer M, Knitza J
Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité Universitätsmedizin, Charitéplatz 1, 10117, Berlin, Deutschland.
Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20253, Hamburg, Deutschland.
Z Rheumatol. 2020 Aug;79(6):554-561. doi: 10.1007/s00393-020-00822-2.
The increasing use of smartphones is accompanied by a significant increase in the use of mobile applications (apps). Chronically ill patients could permanently profit from this development.This development is fuelled by the Digital Healthcare Act (DVG), whereby patients have a legal claim to certain apps, so-called digital health applications (DiGAs), which are reimbursed by the statutory health insurance companies. Especially in the field of rheumatology, there are various opportunities to implement apps in the management of chronic diseases and their comorbidities. Furthermore, rheumatic patients and rheumatologists are becoming interested in apps and are willing to use them in the daily routine. This article tries to shed light on the chances and risks of apps and gives a first insight into the digital landscape of rheumatology apps in Germany.
智能手机使用的日益增加伴随着移动应用程序(应用)使用的显著增长。慢性病患者可以长期从这一发展中受益。《数字医疗法案》(DVG)推动了这一发展,据此患者对某些应用程序拥有法定权利,即所谓的数字健康应用程序(DiGAs),这些应用程序由法定健康保险公司报销。特别是在风湿病领域,在慢性病及其合并症的管理中实施应用程序有各种机会。此外,风湿病患者和风湿病学家对应用程序越来越感兴趣,并愿意在日常工作中使用它们。本文试图阐明应用程序的机遇和风险,并首次深入了解德国风湿病应用程序的数字格局。